Use of Methylsulfonylmethane to treat parasitic infections

• US 4,914,135 A
• Filed: 07/26/1989
• Issued: 04/03/1990
• Est. Priority Date: 08/30/1979
• Status: Expired due to Term

• Current Assignee: Cardinal Associates, Inc. (Balchem Corporation)
• Original Assignee: Robert J. Herschler
• Inventors: Herschler, Robert J.
• Primary Examiner(s): Griffin, Ronald W.
• Application Number:
  US07/385,116
• Time in Patent Office: 251 Days
• Field of Search: 514/711, 424/439
• US Class Current: 514/711
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/10 Sulfides; Sulfoxides; Sulfones
• CPC Class Codes: A61K 31/17 having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64
• CPC Class Codes: A61K 31/7004 Monosaccharides having only carbon, hydrogen and oxygen atoms
• CPC Class Codes: A61K 33/14 Alkali metal chlorides; Alkaline earth metal chlorides
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Methylsulfonylmethane is effective in treating parasitic infections in animals, including human beings.

Claims

1. A method of treating a patient systemically infected with a parasite against which methylsulfonylmethane exhibits in vitro toxicity, which comprises administering systemically to the patient an amount of methylsulfonylmethane effective to inhibit the growth of the parasite in the patient.

2. A method according to claim 1, wherein the methylsulfonylmethane is administered orally.

3. A method according to claim 2, wherein the methylsulfonylmethane is administered repeatedly on successive days.

4. A method according to claim 1, wherein the parasite is pathogenic to the host.

5. A method according to claim 1, wherein the host is a human being.

6. A method according to claim 1, wherein the methylsulfonylmethane is administered orally;

wherein the methylsulfonylmethane is administered repeatedly on successive days;

wherein the parasite is pathogenic to the host; and

wherein the host is a human being.

7. A method according to claim 1, wherein the parasite is Trichomonas vaginalis.

8. A method according to claim 1, wherein the parasite is Giardia lamblia and the host is a human being.

9. A method according to claim 1, wherein the parasite is an intestinal worm.